The paper is a post hocsecondary analysis of a Danish randomized controlled trial that originally tested prenatal vitamin D3 for asthma-related outcomes, not cognition. It followed roughly 500 children to age 10 and reported small positive associations between higher-dose maternal supplementation and a few cognitive measures, mostly in memory. After correction for multiple testing, the abstract says visual memory and verbal memory remained significant while flexibility or set shift did not. That framing drove most of the reaction.
The sharpest read was that this is far weaker than the headline suggests. People zeroed in on the large number of cognitive endpoints, the fact that the study was not designed or powered around cognition, and the mismatch between the cautious-looking paper language and the much stronger implication readers could easily take away. Several commenters argued that once you understand this as exploratory reuse of an existing trial, the right conclusion is simply that prenatal vitamin D is worth testing more directly, not that it improves children's cognition.
A second theme was external validity. The cohort was Danish, which matters here less as a national prestige question than because sunlight exposure, baseline vitamin D status, food fortification, and skin pigmentation all affect how far you can generalize dosage or effect size. Commenters also pushed back on lazy assumptions about Denmark meaning universally low vitamin D, noting the study measured baseline levels and adjusted for them, and that deficiency patterns can be counterintuitive across countries because diet and fortification policies differ. The broad mood was not anti-vitamin D. It was anti-overclaiming from noisy secondary analyses in a field that already attracts a lot of wishful thinking.
Treat this as a hypothesis-generating result, not a basis for product claims, health guidance, or broad neurodevelopment conclusions. If you work with research-heavy health topics, watch for how many outcomes were tested, how multiple-comparison correction was done, and whether the study was actually designed for the endpoint now being promoted.
Mostly skeptical and a bit irritated. The main reasons were that the paper reuses an asthma trial for a different endpoint, tests many cognitive measures, reports only small effects, and still invites a much stronger takeaway than the data justify in a vitamin D area that commenters already see as prone to hype.
Key insights
01
Vitamin D findings live in a publication-bias swamp
Vitamin D gets studied against an enormous range of outcomes because it plausibly touches many body systems. That makes any single modest positive signal hard to trust on its own, since many null follow-ups or failed exploratory analyses may never get published, and this paper does not stand out as a field-settling result in that larger literature.
Do not evaluate a vitamin D paper in isolation. Look for systematic reviews, preregistered replication, and whether the endpoint was primary rather than one more positive result surfacing from a crowded field.
Geography matters through baseline vitamin D, not nationality
Location is relevant here because sunlight, fortification, and time outdoors change vitamin D biology before supplementation even starts. Several commenters pointed out that the study did measure maternal baseline vitamin D and adjusted for it, while others added that northern countries can offset low winter sun through fortification and that indoor sunlight through glass does not make vitamin D because UVB is filtered out.
If you want to apply this result to another population, match on baseline vitamin D status and local fortification patterns before thinking about dose. Latitude alone is too crude and national origin is the wrong variable.
Randomization does not rescue a weak secondary endpoint
Randomization handles confounders like socioeconomic status only for outcomes the trial was properly designed and followed to assess. Once a study pivots years later to a secondary endpoint with limited detail on selection, attrition, and measurement, the fact that the original trial was randomized no longer gives the new claim the same level of credibility as a clean primary analysis.
When you read follow-up analyses of old trials, separate the strength of the original randomization from the strength of the new endpoint. Demand attrition details and a prespecified analysis plan before treating the result like causal evidence.
The least misleading interpretation is that prenatal vitamin D may affect some narrow neurodevelopmental outcomes, not that it makes children broadly smarter. Commenters highlighted that the effect, if real, is modest and local to a couple of memory measures, which is a very different claim from a general improvement in cognition or intelligence.
Avoid broad labels like 'smarter kids' in any downstream use of this study. If you follow the space, watch for targeted replication on specific memory outcomes rather than omnibus cognition claims.
Looking across many outcomes in an existing trial is not automatically misconduct. Used honestly, it is a way to kill weak hypotheses and surface one or two candidates worth testing in a study that is actually built for them.
Do not throw out every post hoc analysis. Classify it correctly and use it to prioritize the next experiment, not to justify practice changes.
The criticism that any correction should wipe out the result depends on how independent the cognitive measures really are. If several scores are correlated for the same child, a blunt whole-battery correction like Bonferroni can be too harsh, and the paper's false discovery rate approach may be more defensible than critics first assumed.
When assessing 'p-hacking' claims, inspect the dependence structure among outcomes and the exact correction method. Bad correction can inflate findings, but overly harsh correction can also hide a real signal.
A single-country cohort does limit generalization, but it does not invalidate the internal comparison if treatment and control groups start from the same place. For a biology question tied to vitamin D levels, a clean estimate within one population can still be useful, and later studies can test whether the same dose-response appears elsewhere.
Separate internal validity from external validity. A narrow cohort can still answer a narrow question well, but you should resist exporting the dose or effect size without replication in other settings.